Short answer · Medically reviewed summary · Last updated: 2026-05-08
Multiple Systems Atrophy (MSA) is a rare, progressive neurodegenerative disorder with an estimated prevalence of approximately 1.9 to 4.4 per 100,000 individuals worldwide. Due to the complexity of the condition, Multiple Systems Atrophy is frequently underdiagnosed or misdiagnosed as Parkinson’s disease, meaning true prevalence rates may be higher than currently reported in clinical literature. What is the incidence and age of onset for Multiple Systems Atrophy? The annual incidence of Multiple Systems Atrophy is estimated at 0.6 to 0.7 per 100,000 person-years.
2 people with Multiple Systems Atrophy have shared their first-person experience on this question at DiseaseMaps.
What is the prevalence of Multiple Systems Atrophy?
Prevalence of Multiple Systems Atrophy: how many people are affected worldwide, differences by sex and region, with sources.
Multiple Systems Atrophy (MSA) is a rare, progressive neurodegenerative disorder with an estimated prevalence of approximately 1.9 to 4.4 per 100,000 individuals worldwide. Due to the complexity of the condition, Multiple Systems Atrophy is frequently underdiagnosed or misdiagnosed as Parkinson’s disease, meaning true prevalence rates may be higher than currently reported in clinical literature.
What is the incidence and age of onset for Multiple Systems Atrophy?
The annual incidence of Multiple Systems Atrophy is estimated at 0.6 to 0.7 per 100,000 person-years. It is strictly an adult-onset condition, typically appearing in the sixth decade of life, with the average age of onset falling between 50 and 60 years. Multiple Systems Atrophy is rarely diagnosed in individuals under the age of 30.
Are there variations in how Multiple Systems Atrophy affects different populations?
Epidemiological data suggests a slight gender bias, with Multiple Systems Atrophy affecting men marginally more often than women. While the disease is global, some studies have noted variations in the prevalence of specific clinical subtypes (MSA-P vs. MSA-C) across different geographic regions, though these differences are often attributed to diagnostic criteria rather than true ethnic predilection.
Why is gathering accurate data on Multiple Systems Atrophy difficult?
Obtaining precise statistics for Multiple Systems Atrophy remains a significant challenge for researchers for several reasons:
- Diagnostic Overlap: Early symptoms often mimic other movement disorders, leading to misdiagnosis.
- Rapid Progression: The aggressive nature of the disease can complicate long-term longitudinal studies.
- Under-reporting: Many cases go unrecognized in primary care settings before referral to specialized neurology centers.
At DiseaseMaps.org, we have seen 911 people with Multiple Systems Atrophy join our community, providing a vital, real-world perspective that complements clinical data by highlighting the lived experience of patients often missed by traditional registries.
Next steps
- Consult a movement disorder specialist or neurologist to discuss diagnostic criteria.
- Join the DiseaseMaps.org community to connect with other families navigating Multiple Systems Atrophy.
- Review resources from the NIH GARD for information on current clinical trials and research opportunities.
Medical disclaimer: This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment; always seek the advice of your physician regarding a medical condition.
References
- Orphanet: Rare Disease Database (ORPHA:587)
- NIH Genetic and Rare Diseases Information Center (GARD)
- OMIM (Online Mendelian Inheritance in Man) entry for Multiple System Atrophy
- The Multiple System Atrophy Coalition
Posted Jul 11, 2017 by Pam Bower 2952
Posted Mar 23, 2018 by [email protected] 3020
